铁酶抑制剂的临床研究:过去,现在和未来
Yuanyuan Wang1, Ruijia Jiang2, Baichen Xiong2
1Department of Medicinal Chemistry, Nanjing Medical University, Nanjing, People's Republic of China.
Drug development research
|June 16, 2025
概括
铁酶酶抑制是治疗各种疾病的有希望的策略,包括皮肤疾病和帕金森病. 本综述综合了铁酶抑制剂的数据,探索了它们的治疗潜力和未来的发展.
科学领域:
- 生物化学和分子生物学
- 酶学 是一种酶学.
- 药理学 药理学是指药理学的学科.
背景情况:
- 铁酶 (EC 1.14.18.1) 催化黑色素生物合成,这是一种涉及皮肤健康,免疫调节和各种疾病的过程.
- 黑色素产生的失调与白风,黑色素瘤和帕金森病等疾病有关.
- 铁酶还在免疫反应中发挥作用,在免疫治疗中具有潜在的应用.
研究的目的:
- 系统地审查铁酶的分类,结构,功能和相关疾病机制.
- 综合研究铁酶抑制剂的治疗机制,病史和临床状况.
- 突出突出研究进展,挑战,和未来的方向,在铁酶抑制剂的发展.
主要方法:
- 充分利用BRENDA数据库中关于铁酶的综合数据.
- 系统审查有关铁酶抑制剂的文献,包括临床前和临床研究.
- 对治疗机制,发展史和当前临床状况的分析.
主要成果:
- 铁酶抑制为皮肤美白,黑色素瘤,,帕金森病,黑色素瘤和免疫疗法耐药性提供了治疗潜力.
- 已经收集了大量关于铁酶在生物过程和疾病机制中的作用的数据.
- 目前的研究包括动物模型,临床前研究和人类临床试验,用于各种适应症.
结论:
- 铁酶抑制是一种具有广泛应用的多功能治疗策略.
- 为了应对当前的挑战,需要进一步研究和优化铁酶抑制剂.
- 本次审查强调了针对不同医疗需求的针对性铁酶的显著治疗潜力.
相关概念视频
Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
Clinical Trials
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
There are four phases in a clinical trial. A phase one...
Clinical Trials: Overview
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...


